Osteoporosis: The emperor has no clothes

Journal of Internal Medicine

Volumn 277, Issue 6, 2015, Pages 662-673

  Jarvinen T L N ^a   Michaelsson K ^b   Aspenberg, P ^c   Sievanen H ^d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UPPSALA UNIVERSITY   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d UKK INSTITUTE FOR HEALTH PROMOTION RESEARCH   (Finland)

Author keywords

Cost effectiveness; Osteoporosis; Prediction; Screening; Treatment

Indexed keywords

ARTICLE; BONE DENSITOMETRY; BONE FRAGILITY; FALLING; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MORTALITY; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SPINE FRACTURE; AGING; BONE DENSITY; EVIDENCE BASED MEDICINE; FEMALE; FRACTURES, BONE; HIP FRACTURES; LITERATURE; MALE; RISK FACTOR; SPINAL FRACTURES; TREATMENT OUTCOME;

ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

AGING; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; EVIDENCE-BASED MEDICINE; FEMALE; FRACTURES, BONE; HIP FRACTURES; HUMANS; MALE; METAPHOR; OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTORS; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 84929646257     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12366     Document Type: Article

References (105)

1. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994; 4: 368-81.
2. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254-9.
3. Stone KL, Seeley DG, Lui LY et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 2003; 18: 1947-54.
4. Black DM, Steinbuch M, Palermo L et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 2001; 12: 519-28.
5. Johnell O, Kanis JA, Oden A et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20: 1185-94.
6. De Laet CE, van Hout BA, Burger H, Hofman A, Pols HA. Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 1997; 315: 221-5.
7. Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 2000; 27: 585-90.
8. Jarvinen TL, Sievanen H, Khan KM, Heinonen A, Kannus P. Shifting the focus in fracture prevention from osteoporosis to falls. BMJ 2008; 336: 124-6.
9. Oudshoorn C, Hartholt KA, Zillikens MC et al. Emergency department visits due to vertebral fractures in the Netherlands, 1986-2008: steep increase in the oldest old, strong association with falls. Injury 2011; 43: 458-61.
10. Wagner H, Melhus H, Gedeborg R, Pedersen NL, Michaelsson K. Simply ask them about their balance-future fracture risk in a nationwide cohort study of twins. Am J Epidemiol 2009; 169: 143-9.
11. Nordstrom P, Eklund F, Bjornstig U et al. Do both areal BMD and injurious falls explain the higher incidence of fractures in women than in men? Calcif Tissue Int 2011; 89: 203-10.
12. Kannus P, Sievanen H, Palvanen M, Jarvinen T, Parkkari J. Prevention of falls and consequent injuries in elderly people. Lancet 2005; 366: 1885-93.
13. Tinetti ME. Clinical practice. Preventing falls in elderly persons. N Engl J Med 2003; 348: 42-9.
14. Cederholm T, Cruz-Jentoft AJ, Maggi S. Sarcopenia and fragility fractures. Eur J Phys Rehabil Med 2013; 49: 111-7.
15. Lang T, Cauley JA, Tylavsky F et al. Computed tomographic measurements of thigh muscle cross-sectional area and attenuation coefficient predict hip fracture: the health, aging, and body composition study. J Bone Miner Res 2010; 25: 513-9.
16. Moore AZ, Caturegli G, Metter EJ et al. Difference in muscle quality over the adult life span and biological correlates in the Baltimore Longitudinal Study of Aging. J Am Geriatr Soc 2014; 62: 230-6.
17. Flicker L, Hopper JL, Rodgers L, Kaymakci B, Green RM, Wark JD. Bone density determinants in elderly women: a twin study. J Bone Miner Res 1995; 10: 1607-13.
18. Videman T, Levalahti E, Battie MC, Simonen R, Vanninen E, Kaprio J. Heritability of BMD of femoral neck and lumbar spine: a multivariate twin study of Finnish men. J Bone Miner Res 2007; 22: 1455-62.
19. Wagner H, Melhus H, Pedersen NL, Michaelsson K. Genetic influence on bone phenotypes and body composition: a Swedish twin study. J Bone Miner Metab 2013; 31: 681-9.
20. Moayyeri A, Hammond CJ, Hart DJ, Spector TD. Effects of age on genetic influence on bone loss over 17 years in women: the Healthy Ageing Twin Study (HATS). J Bone Miner Res 2012; 27: 2170-8.
21. Michaelsson K, Melhus H, Ferm H, Ahlbom A, Pedersen NL. Genetic liability to fractures in the elderly. Arch Intern Med 2005; 165: 1825-30.
22. Kannus P, Palvanen M, Kaprio J, Parkkari J, Koskenvuo M. Genetic factors and osteoporotic fractures in elderly people: prospective 25 year follow up of a nationwide cohort of elderly Finnish twins. BMJ 1999; 319: 1334-7.
23. Cummings SR, Nevitt MC, Browner WS et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332: 767-73.
24. Paternoster L, Lorentzon M, Lehtimaki T et al. Genetic determinants of trabecular and cortical volumetric bone mineral densities and bone microstructure. PLoS Genet 2013; 9: e1003247.
25. Koller DL, Zheng HF, Karasik D et al. Meta-analysis of genome-wide studies identifies WNT16 and ESR1 SNPs associated with bone mineral density in premenopausal women. J Bone Miner Res 2013; 28: 547-58.
26. Estrada K, Styrkarsdottir U, Evangelou E et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet 2012; 44: 491-501.
27. Alonso N, Ralston SH. Unveiling the mysteries of the genetics of osteoporosis. J Endocrinol Invest 2014; 37: 925-34.
28. Wagner H, Melhus H, Pedersen NL, Michaelsson K. Heritability of impaired balance: a nationwide cohort study in twins. Osteoporos Int 2009; 20: 577-83.
29. Pajala S, Era P, Koskenvuo M, Kaprio J, Tolvanen A, Rantanen T. Genetic and environmental contribution to postural balance of older women in single and dual task situations. Neurobiol Aging 2007; 28: 947-54.
30. Hernlund E, Svedbom A, Ivergard M et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013; 8: 136.
31. Wahl DA, Cooper C, Boonen S. Clinicians need to treat underlying osteoporosis. BMJ 2011; 343: d5040.
32. Melton LJ 3rd, Wenger DE, Atkinson EJ et al. Influence of baseline deformity definition on subsequent vertebral fracture risk in postmenopausal women. Osteoporos Int 2006; 17: 978-85.
33. Cooper C, Atkinson EJ, Kotowicz M, O'Fallon WM, Melton LJ 3rd. Secular trends in the incidence of postmenopausal vertebral fractures. Calcif Tissue Int 1992; 51: 100-4.
34. Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ 3rd. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 1992; 7: 221-7.
35. Myers ER, Wilson SE. Biomechanics of osteoporosis and vertebral fracture. Spine 1997; 24(Suppl): 25S-31S.
36. Oudshoorn C, Hartholt KA, Zillikens MC et al. Emergency department visits due to vertebral fractures in the Netherlands, 1986-2008: steep increase in the oldest old, strong association with falls. Injury 2012; 43: 458-61.
37. Duan Y, Seeman E, Turner CH. The biomechanical basis of vertebral body fragility in men and women. J Bone Miner Res 2001; 16: 2276-83.
38. Cooper C, O'Neill T, Silman A. The epidemiology of vertebral fractures. European Vertebral Osteoporosis Study Group. Bone 1993; 14(Suppl 1): S89-97.
39. O'Neill TW, Cockerill W, Matthis C et al. Back pain, disability, and radiographic vertebral fracture in European women: a prospective study. Osteoporos Int 2004; 15: 760-5.
40. Kherad M, Rosengren BE, Hasserius R et al. There is low clinical relevance of a prevalent vertebral fracture in old men - the MrOs Sweden study. Spine J 2014; 15: 281-9.
41. Sattui SE, Saag KG. Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 2014; 10: 592-602.
42. Michaelsson K, Nordstrom P, Nordstrom A et al. Impact of hip fracture on mortality: a cohort study in hip fracture discordant identical twins. J Bone Miner Res 2014; 29: 424-31.
43. Haentjens P, Magaziner J, Colon-Emeric CS et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010; 152: 380-90.
44. Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-809.
45. Colon-Emeric CS, Mesenbrink P, Lyles KW et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 2010; 25: 91-7.
46. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22.
47. Browner WS. Predicting fracture risk: tougher than it looks. Bonekey Osteovision 2007; 4: 226-30.
48. Bolotin HH, Sievanen H. Inaccuracies inherent in dual-energy X-ray absorptiometry in vivo bone mineral density can seriously mislead diagnostic/prognostic interpretations of patient-specific bone fragility. J Bone Miner Res 2001; 16: 799-805.
49. Blake GM, Fogelman I. How important are BMD accuracy errors for the clinical interpretation of DXA scans? J Bone Miner Res 2008; 23: 457-62.
50. Svendsen OL, Hassager C, Skodt V, Christiansen C. Impact of soft tissue on in vivo accuracy of bone mineral measurements in the spine, hip, and forearm: a human cadaver study. J Bone Miner Res 1995; 10: 868-73.
51. Compston J. Monitoring bone mineral density during antiresorptive treatment for osteoporosis. BMJ 2009; 338: b1276.
52. Kanis JA, on behalf of the World Health Organization Scientific Group. Assesment of Osteoporosis at the Primary Health-Care Level. Technical report. WHO Collaborating Center for Metabolic Bone Diseases. University of Sheffield, 2008.
53. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19: 385-97.
54. Kanis JA, Oden A, Johnell O et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007; 18: 1033-46.
55. Collins GS, Michaelsson K. Fracture risk assessment: state of the art, methodologically unsound, or poorly reported? Curr Osteoporos Rep 2012; 10: 199-207.
56. Bolland MJ, Grey A, Gamble G, Reid IR. Comment on Kanis et al.: pitfalls in the external validation of FRAX. Osteoporos Int 2013; 24: 389-90.
57. Bolland MJ, Siu AT, Mason BH et al. Evaluation of the FRAX and Garvan fracture risk calculators in older women. J Bone Miner Res 2011; 26: 420-7.
58. Jarvinen TL, Jokihaara J, Guy P et al. Conflicts at the heart of the FRAX tool. CMAJ 2014; 186: 165-7.
59. Donaldson MG, Cawthon PM, Lui LY et al. Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. J Bone Miner Res 2009; 24: 675-80.
60. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis (available at http://www.nof.org/sites/default/files/pdfs/NOF_ClinicianGuide2009_v7.pdf), 2010.
61. National Osteoporosis Guideline Group (NOGG). Osteoporosis: clinical guidelines for prevention and treatment. Executive Summary, 2010.
62. Papaioannou A, Morin S, Cheung AM et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010; 182: 1864-73.
63. Rabar S, Lau R, O'Flynn N, Li L, Barry P, Guideline Development Group. Risk assessment of fragility fractures: summary of NICE guidance. BMJ 2012; 345: e3698.
64. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333-40.
65. Moons KG, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ 2009; 338: b606.
66. Cummings S, Donaldson M, Palermo L et al. Efficacy of alendronate for reducing nonvertebral and clinical fractures by FRAX score. The American Society for Bone and Mineral Reseach: 31st Annual Meeting Abstract, 2009.
67. Haynes B. Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving. BMJ 1999; 319: 652-3.
68. Jarvinen TL, Sievanen H, Kannus P, Jokihaara J, Khan KM. The true cost of pharmacological disease prevention. BMJ 2011; 342: d2175.
69. EMA. E. Aclasta EMEA-H-595-II-10-AR. Secondary Aclasta EMEA-H-595-II-10-AR, 2007. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion_-_Variation/human/000595/WC500020937.pdf.
70. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008; 19: 437-47.
71. Pham AN, Datta SK, Weber TJ, Walter LC, Colon-Emeric CS. Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy. J Am Geriatr Soc 2011; 59: 1642-9.
72. Boonen S, Dejaeger E, Vanderschueren D et al. Osteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective. Best Pract Res Clin Endocrinol Metab 2008; 22: 765-85.
73. Watts G. Why the exclusion of older people from clinical research must stop. BMJ 2012; 344: e3445.
74. Feldstein AC, Weycker D, Nichols GA et al. Effectiveness of bisphosphonate therapy in a community setting. Bone 2009; 44: 153-9.
75. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009; 24: 1095-102.
76. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010; 95: 5258-65.
77. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364: 1728-37.
78. Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101 038 new bisphosphonate users. J Bone Miner Res 2008; 23: 1435-41.
79. Erviti J, Alonso A, Gorricho J, Lopez A. Oral bisphosphonates may not decrease hip fracture risk in elderly Spanish women: a nested case-control study. BMJ Open 2013; 3: pii:e002084. doi:10.1136/bmjopen-2012-002084.
80. Crilly RG, Kloseck M, Chesworth B, Mequanint S, Sadowski E, Gilliland J. Comparison of hip fracture and osteoporosis medication prescription rates across Canadian provinces. Osteoporos Int 2014; 25: 205-10.
81. Musini VM, Bassett KL, Wright JM. A systematic review of the efficacy of bisphosphonates. Ther Lett 2011. Available at: www.ti.ubc.ca/letter83.
82. Bone HG, Downs RW Jr, Tucci JR et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab 1997; 82: 265-74.
83. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82.
84. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41.
85. Qin L, Choy W, Au S, Fan M, Leung P. Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis. J Orthop Surg Res 2007; 2: 9.
86. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294-301.
87. Shane E, Burr D, Abrahamsen B et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the american society for bone and mineral research. J Bone Miner Res 2014; 29: 1-23.
88. Feldstein AC, Black D, Perrin N et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 2012; 27: 977-86.
89. Rydholm A. Highly different risk estimates for atypical femoral fracture with use of bisphosphonates - debate must be allowed!. Acta Orthop 2012; 83: 319-20.
90. Black DM, Kelly MP, Genant HK et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010; 362: 1761-71.
91. Talley C, Kushner HI, Sterk CE. Lung cancer, chronic disease epidemiology, and medicine, 1948-1964. J Hist Med Allied Sci 2004; 59: 329-74.
92. Services USDoHaH. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA, USA: Services USDoHaH, 2004.
93. Rose G, Hamilton PJ. A randomised controlled trial of the effect on middle-aged men of advice to stop smoking. J Epidemiol Community Health 1978; 32: 275-81.
94. Schilcher J, Koeppen V, Aspenberg P, Michaelsson K. Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med 2014; 371: 974-6.
95. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2014; 364: 1728-37.
96. WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. WHO Technical Report Series, Report No. 843. WHO, Geneva, Switzerland, 1994.
97. Cooper C, Aihie A. Osteoporosis: recent advances in pathogenesis and treatment. Q J Med 1994; 87: 203-9.
98. Callard F, Bracken P, David AS, Sartorius N. Has psychiatric diagnosis labelled rather than enabled patients? BMJ 2013; 347: f4312.
99. Haynes RB, Sackett DL, Taylor DW, Gibson ES, Johnson AL. Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med 1978; 299: 741-4.
100. Spence D. Undoing diagnoses. BMJ 2011; 342: d3751.
101. Rubin SM, Cummings SR. Results of bone densitometry affect women's decisions about taking measures to prevent fractures. Ann Intern Med 1992; 116(12 Pt 1): 990-5.
102. Law MR, Wald NJ, Meade TW. Strategies for prevention of osteoporosis and hip fracture. BMJ 1991; 303: 453-9.
103. Ioannidis JP. How many contemporary medical practices are worse than doing nothing or doing less? Mayo Clin Proc 2013; 88: 779-81.
104. Prasad V, Vandross A, Toomey C et al. A decade of reversal: an analysis of 146 contradicted medical practices. Mayo Clin Proc 2013; 88: 790-8.
105. Sievanen H, Kannus P, Jarvinen TL. Bone quality: an empty term. PLoS Med 2007; 4: e27.